Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Proteome Sciences plc    PRM   GB0003104196

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
04/19/2017 04/20/2017 04/21/2017 04/24/2017 04/25/2017 Date
4.5(c) 4.5(c) 4.5(c) 4.51(c) 4.277 Last
0 9 680 90 000 434 260 971 146 Volume
-0.11% 0.00% 0.00% +0.22% -5.17% Change
More quotes
Financials ( GBP)
Sales 2017 4,10 M
EBIT 2017 -1,60 M
Net income 2017 -1,40 M
Debt 2017 7,40 M
Yield 2017 -
Sales 2018 5,50 M
EBIT 2018 -1,00 M
Net income 2018 0,10 M
Debt 2018 7,70 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 45,10
EV / Sales2017 5,05x
EV / Sales2018 3,82x
Capitalization 13,3 M
More Financials
Company
Proteome Sciences Plc is engaged in applied proteomics and peptidomics services and applications.It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development.The company focuses on developing proprietary protein biomarkers for neurological... 
More about the company
Latest news on PROTEOME SCIENCES PLC
04/03 PROTEOME SCIENCES : Appoints Richard Dennis Chief Commercial Officer
04/03 PROTEOME SCIENCES : Appointment of Richard Dennis as Chief Commercial Officer
03/31 PROTEOME SCIENCES : Annual Report and Accounts 2016
03/28 PROTEOME SCIENCES : Says "Much Yet To Do" As Loss Narrows In 2016
03/28 PROTEOME SCIENCES : Preliminary results for the year ended 31 December 2016 Noti..
03/23PROTEOME SCIENCES PLC : annual earnings release
02/09 PROTEOME SCIENCES : Trading Update and Notice of Results
02/09 PROTEOME SCIENCES : Expects Narrowed Loss, Appoints Commercial Officer
01/05 PROTEOME SCIENCES : Holdings in Company and PDMR Shareholding
01/03 DIRECTOR DEALINGS SUMMARY : Proteome Sciences Non-Executive Lifts Stake
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
Latest Tweets
03/31Proteome Sciences : Annual Report and Accounts 2016  
03/28Proteome Sciences revenue rises in full year results  
03/28Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
03/28Proteome Sciences : Preliminary results for the year ended 31 December 2016 N.. 
02/24Proteome Sciences plc's corporate rating reiterated at FinnCap. GBX 12 PT.  
More tweets
Qtime:5
Advertisement
Chart PROTEOME SCIENCES PLC
Duration : Period :
Proteome Sciences plc Technical Analysis Chart | PRM | GB0003104196 | 4-Traders
Full-screen chart
Technical analysis trends PROTEOME SCIENCES...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jeremy Rupert Michael Haigh Chief Executive Officer & Executive Director
Christopher D. J. Pearce Executive Chairman
Ian H. Pike Chief Operating Officer & Executive Director
Geoffrey John Ellis Secretary, Executive & Finance Director
Malcolm Ward Chief Technical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOME SCIENCES PLC-18.00%17
AMGEN, INC.11.58%120 053
CELGENE CORPORATION6.39%95 807
GILEAD SCIENCES, INC.-7.49%86 604
REGENERON PHARMACEUTIC..0.83%39 455
ACTELION LTD26.98%30 323
More Results